Literature DB >> 17584298

Hepatitis delta antigen binds to the clamp of RNA polymerase II and affects transcriptional fidelity.

Yuki Yamaguchi1, Takashi Mura, Sittinan Chanarat, Sachiko Okamoto, Hiroshi Handa.   

Abstract

Hepatitis delta virus (HDV) is an RNA virus whose replication and transcription are considered to proceed via RNA-dependent RNA synthesis by RNA polymerase II (Pol II), and the viral protein called hepatitis delta antigen (HDAg) is essential for these processes. HDAg was previously shown to stimulate Pol II elongation on both DNA and RNA templates in vitro. Here, the mechanism of elongation control by HDAg was investigated because it serves as a prototype of cellular transcription elongation factors and also plays an interesting role in HDV proliferation. With site-specific photocrosslinking and transcription using reconstituted elongation complexes, evidence is presented that HDAg functionally interacts with the clamp of Pol II, a mobile structure that holds DNA and RNA in place. Strikingly, HDAg not only increases the rate of elongation but also affects the decision of which nucleotide is incorporated. These and our previous findings lead us to propose a model in which HDAg interacts with and loosens the clamp, and thereby accelerates forward translocation of Pol II at the cost of fidelity. By reducing transcriptional fidelity in terms of not only discrimination of incoming nucleotides but also recognition of templates, HDAg may facilitate the unusual RNA-dependent RNA synthesis by Pol II.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17584298     DOI: 10.1111/j.1365-2443.2007.01094.x

Source DB:  PubMed          Journal:  Genes Cells        ISSN: 1356-9597            Impact factor:   1.891


  24 in total

1.  Interactions between DSIF (DRB sensitivity inducing factor), NELF (negative elongation factor), and the Drosophila RNA polymerase II transcription elongation complex.

Authors:  Anamika Missra; David S Gilmour
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-04       Impact factor: 11.205

2.  Transcription of hepatitis delta virus RNA by RNA polymerase II.

Authors:  Jinhong Chang; Xingcao Nie; Ho Eun Chang; Ziying Han; John Taylor
Journal:  J Virol       Date:  2007-11-21       Impact factor: 5.103

3.  Wild-type is the optimal sequence of the HDV ribozyme under cotranscriptional conditions.

Authors:  Durga M Chadalavada; Andrea L Cerrone-Szakal; Philip C Bevilacqua
Journal:  RNA       Date:  2007-10-23       Impact factor: 4.942

Review 4.  Host RNA circles and the origin of hepatitis delta virus.

Authors:  John M Taylor
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

5.  RNA Polymerase Clamp Movement Aids Dissociation from DNA but Is Not Required for RNA Release at Intrinsic Terminators.

Authors:  Michael J Bellecourt; Ananya Ray-Soni; Alex Harwig; Rachel Anne Mooney; Robert Landick
Journal:  J Mol Biol       Date:  2019-01-08       Impact factor: 5.469

Review 6.  Control of ADAR1 editing of hepatitis delta virus RNAs.

Authors:  John L Casey
Journal:  Curr Top Microbiol Immunol       Date:  2012       Impact factor: 4.291

7.  Combined proteomic-RNAi screen for host factors involved in human hepatitis delta virus replication.

Authors:  Dan Cao; Dirk Haussecker; Yong Huang; Mark A Kay
Journal:  RNA       Date:  2009-09-23       Impact factor: 4.942

8.  RNA polymerase II flexibility during translocation from normal mode analysis.

Authors:  Michael Feig; Zachary F Burton
Journal:  Proteins       Date:  2010-02-01

9.  Phosphorylation of serine 177 of the small hepatitis delta antigen regulates viral antigenomic RNA replication by interacting with the processive RNA polymerase II.

Authors:  Shiao-Ya Hong; Pei-Jer Chen
Journal:  J Virol       Date:  2009-11-18       Impact factor: 5.103

10.  Millisecond phase kinetic analysis of elongation catalyzed by human, yeast, and Escherichia coli RNA polymerase.

Authors:  Maria Kireeva; Yuri A Nedialkov; Xue Qian Gong; Chunfen Zhang; Yalin Xiong; Woo Moon; Zachary F Burton; Mikhail Kashlev
Journal:  Methods       Date:  2009-05-04       Impact factor: 3.608

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.